Previous Speakers (2022 part 2)

Some seminars were recorded and accessible for a limited time on our youtube channel.

Ebert headshot.jpg

Benjamin L. Ebert, MD, PhD

Dana-Farber Cancer Institute


September 1, 2022  - 4:00 PM EST

Targeted protein degradation for the treatment of cancer

Host: Mikołaj Słabicki / Katherine Donovan


Time Change:

4 PM (EDT) / 1 PM (PT) , 
9 pm (BST), 10 pm (CEST) 

Dr. Benjamin Ebert is the Chair of Medical Oncology at the Dana-Farber Cancer Institute, the George P. Canellos, MD and Jean S. Canellos Professor of Medicine at Harvard Medical School, a Howard Hughes Medical Institute Investigator, and an Institute Member of the Broad Institute.


The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies and its non-malignant precursor conditions, with a particular focus on myelodysplastic syndromes (MDS) and clonal hematopoiesis.  The Ebert laboratory demonstrated that lenalidomide, a derivative of thalidomide, binds the CRL4-CRBN E3 ubiquitin ligase and induces degradation of specific substrates.  Subsequent research has examined novel mechanisms of drug-induced protein degradation that expand the spectrum of protein substrates that can be targeted pharmacologically.


Dr. Ebert is an elected member of the National Academy of Medicine, the American Society for Clinical Investigation and the Association of American Physicians.  He served as President of the American Society for Clinical Investigation in 2017.  He received the William Dameshek Prize from the American Society of Hematology in 2017, the Meyenburg Prize for Cancer Research in 2019, the Sjöberg Prize from the Royal Swedish Academy of Sciences in 2021, and the Korsmeyer Award from the American Society for Clinical Investigation in 2021.


Dr. Ebert received a bachelor's degree from Williams College and a doctorate from Oxford University as a Rhodes Scholar in the laboratory of Sir Peter Ratcliffe.  He completed an M.D. from Harvard Medical School, a residency in internal medicine at Massachusetts General Hospital, and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute.

This event will be held on-site and broadcast virtually via Zoom.
A reception will be held on-site after the talk from 5:10- 7:30 PM (EDT).

Event Location:  

Linda K. Paresky Conference Center, Simmons University 300 Fenway Boston, MA 02115

There is a limited number of registration slots available and is based on the seminar room capacity. Registration will work on a first come first served basis. Registration is free of charge, but please cancel your registration (drop line to if you cannot join to allow space for others.

Sponsored by:


September 15, 2022  

Chemical biology studies of the thalidomide binding domain of cereblon

Host: Mikołaj Słabicki / Xiaoxi Liu


Abstract: The E3 ligase adaptor cereblon is a target of thalidomide and lenalidomide, therapeutic agents that are used in the treatment of hematopoietic cancers despite teratogenic toxicity.  These agents act in part by modulating substrate selection and degradation through the thalidomide binding domain of cereblon.  However, despite the expanding use of cereblon in targeted protein degradation technologies, identification of a degron, the recognition domain that controls the endogenous substrate selection mechanisms of cereblon, has remained elusive. Here, I will describe chemoproteomics approaches to target identification in the study of molecular glues like lenalidomide, and how these chemical biology approaches can reveal new insights about the thalidomide binding domain of cereblon.

Biosketch: Christina M. Woo is an Associate Professor in the Department of Chemistry and Chemical Biology at Harvard University, and an affiliate member of the Broad Institute.  Christina’s research focuses on the design of small molecule and protein approaches to alter post-translational modifications and the signaling outcomes they produce. She obtained a BA in Chemistry from Wellesley College (2008) and conducted undergraduate research with Professor Dora Carrico-Moniz.  She obtained her PhD in 2013 from Yale University under the guidance of Professor Seth B. Herzon as an NSF predoctoral fellow in the synthetic and chemical biology studies of diazofluorene antitumor antibiotics.  In 2013, Christina joined the laboratory of Professor Carolyn R. Bertozzi at the University of California Berkeley as a Jane Coffins Child postdoctoral fellow and continued at Stanford University (2015) as a Burroughs Wellcome Fund postdoctoral fellow, where she developed a mass-independent chemical glycoproteomics platform for the identification of non-templated post-translational modifications.  Christina joined the faculty at Harvard University in 2016.  Her research has been recognized by the Camille-Dreyfus Teacher-Scholar Award, Sloan Research Foundation, NSF CAREER, Bayer Early Excellence in Science Award, the NIH DP1 Avenir Award, and the Ono Pharma Foundation Breakthrough Science Award.